Yelena Y. Janjigian, Hirokazu Shoji, Anna Kowalczyk, Sun Young Rha, Filippo Pietrantonio, Kohei Shitara, Aitana Calvo Ferrándiz, Hanneke W.M. van Laarhoven, Tianshu Liu, Boguslawa Karaszewska, Keun-Wook Lee, Kathia Cristina Abdalla, Eric Xueyu Chen, Jamil Asselah, M. Luisa Limon, Megan Scott, Caron Lloyd, Eric Nwazue, Roy Rabbie, Jeeyun Lee. "First-line (1L) trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.4022